Sun Pharmaceutical Industries Limited Regd Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara-390020 Corporate

Office : Acme Plaza, Andheri-Kurla Road, Andheri (E), Mumbai - 400059 Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2010
Quarter ended 31.12.2010 31.12.2009 Unaudited Unaudited Income Net Sales / Income from Operations Other operating Income Other operating Income Total Income Expenditure (Increase) // Decrease in Stock in trade and work in progress (Increase) Decrease in Stock in trade and work in progress Consumption of Materials Consumption of Materials Purchase of Traded Goods Purchase of Traded Goods Employees' Cost Employees' Cost Other Indirect Taxes Other Indirect Taxes Depreciation // Amortisation Depreciation Amortisation Other Expenditure Other Expenditure Total Expenditure Profit from Operations before Other Income, Interest & Tax Other Income Other Income Profit before Interest & Tax Net Interest Income Net Interest Income Profit after Interest but before Tax Tax Expense Tax Expense Net Profit for the period from ordinary activities after tax Paid-up Equity Share Capital Equity Shares - Face Value ` 1 each (Previous periods ` 5 each) Reserves excluding Revaluation Reserve (As per last Audited Balance Sheet) Earnings Per Share of ` 1 each - in ` (Basic & Diluted) Public Shareholding No. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Shareholding Promoters and Promoter Group Shareholding a) Pledged / Encumbered No. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group) Percentage of Equity Shares (as a % of the total share capital of the Company) b) Non-encumbered No. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group) Percentage of Equity Shares (as a % of the total share capital of the Company) Research & Development Expenses incurred (included above) 45,826 30,231 76,057 2,310 12,396 5,012 6,313 1,099 1,820 16,575 45,525 30,532 1,051 31,583 3,858 35,441 1,174 34,267 10,356 48,964 21,280 70,244 (950) 14,287 5,254 5,237 1,025 1,540 13,555 39,948 30,296 1,349 31,645 2,141 33,786 1,982 31,804 10,356 Nine Months ended 31.12.2010 31.12.2009 Unaudited Unaudited 146,930 85,801 232,731 3,600 50,610 13,715 19,067 3,492 4,840 45,078 140,402 92,329 5,483 97,812 8,701 106,513 5,411 101,102 10,356 136,991 47,341 184,332 (1,972) 50,980 9,653 15,686 2,738 4,928 37,716 119,729 64,603 (5,016) 59,587 8,441 68,028 3,767 64,261 10,356 ( ` in Lakhs) Year ended 31.03.2010 Audited 184,613 67,766 252,379 (3,091) 70,926 13,704 21,215 3,828 6,947 52,931 166,460 85,919 (1,488) 84,431 10,485 94,916 5,051 89,865 10,356 561,442 8.7 75,150,451 36.28

3.3 375,751,755 36.29

3.1 75,154,439 36.29

9.8 375,751,755 36.29

6.2 75,154,439 36.29

2,105,000 0.32 0.20 657,725,200 99.68 63.51 3,697

810,500 0.61 0.39 131,151,452 99.39 63.32 3,652

2,105,000 0.32 0.20 657,725,200 99.68 63.51 11,840

810,500 0.61 0.39 131,151,452 99.39 63.32 10,180

685,000 0.52 0.33 131,280,940 99.48 63.39 14,408

1 The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 31, 2011 and have been subjected to a Limited Review by the Statutory Auditors of the Company. 2 Consequent to the approval of the members of the Company and upon requisite regulatory compliance, during the quarter, one equity share of ` 5 each of the Company is sub-divided into five equity shares of ` 1 each fully paid up. The Earnings Per Share of ` 1 each has been restated for all the corresponding periods in accordance with Accounting Standard (AS-20) on 'Earnings Per Share" as notified under The Companies (Accounting Standards) Rules, 2006. 3 Other Operating Income represents Share of Income from Partnership Firms. 4 The Company has only one reportable business segment namely 'Pharmaceuticals'. 5 Tax Expense includes Current Tax and Deferred Tax. 6 Status of investor complaints [in nos.] during the quarter, pursuant to clause 41 of the listing agreement: Opening [0]; Received [7]; Resolved [7]; Closing [0]. 7 Figures for the previous period / year have been regrouped / reclassified, wherever considered necessary.

By order of the Board

Mumbai, January 31, 2011

Dilip S Shanghvi Chairman and Managing Director

137 85.452 99.03.277 410.32 0. Accordingly.bseindia.086 102.807 5.142 216.3 75.760 810.51 21.535 13.03.932 152.755 36.222 41.12.454 6.084 437.015 10.012 141.com) and the key information on standalone financial results are as below: Quarter ended 31.151.950 9.585 115.221 15.786 34.332 106.715 54.824 3.755 36.10 31.940 99.327 120.500 0.397) 28.267 31.356 13.031 8. which have been subjected to a Limited Review by the Statutory Auditors are available on the Company's website (www.389 141.425 300.537 8. the above results for the current periods includes the relevant results of Taro and its subsidiaries from the date Taro became subsidiary of the Company and therefore the corresponding figures for the previous periods are not comparable.379 94.552 8.497 2.12. Shanghvi Chairman & Managing Director . 3 Consequent to the approval of the members of the Company and upon requisite regulatory compliance.484 6.] during the quarter.359 1. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group) Percentage of Equity Shares (as a % of the total share capital of the Company) Research & Development Expenses incurred (included above) Notes: 160.20 657. Received [7]. Office : Sun Pharma Advanced Research Centre.963 8.39 24.362 (13.047 68.sunpharma.28 2.101 36. 2 Consolidation has been made by applying Accounting Standard 21 – "Consolidated Financial Statements" as notified by Companies (Accounting Standards) Rules.892 (3) 33.61 0.356 772.277 (3.331 115. Mumbai .12.281) 86.280.20 657.579 38.12.150.865 Total Income from operations Profit before Tax Profit after Tax 7 Status of investor complaints [in nos. a pharmaceutical company.10 31. By Order of the Board Mumbai.890 685.32 0.51 8.912 95. 2010. pursuant to the clause 41 of the listing agreement : Opening [0].698 (410) 135.323 13.09 Unaudited Unaudited 232.107 807 37.834 33.000 0.154.555 15.68 63. Andheri-Kurla Road.451 36.047 45.716 5.com) and NSE (www.796 2.61 0.804 Nine Months ended 31.722 1 The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 31.448 36. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Shareholding Promoters and Promoter Group Shareholding a) Pledged / Encumbered No.102 64.262 144.29 299.542 (118) 95.315 136. January 31st.taro.439 36.086 (5.812 10.10 31.48 63.769 7.10 31.10 Audited 410. 2011 Dilip S.306) 102.795 9.660 10.439 36.400059 Consolidated Unaudited Financial Results for the Quarter and Nine Months ended December 31.09 Unaudited Unaudited Income Net Sales / Income from Operations Total Income Expenditure (Increase) / Decrease in Stock in Trade and work in progress Consumption of Materials Purchase of Traded Goods Employees' Cost Depreciation / Amortisation Other Expenditure Total Expenditure Profit from Operations before Other Income.725. 2010 Quarter ended 31.2 75.513 68. Vadodara . Tandalja.786 134.154. 2011.362 299.012 27.105.29 Nine Months ended 31. The Earnings Per Share of ` 1 each has been restated for all the corresponding periods in accordance with Accounting Standard (AS-20) on 'Earnings Per Share" as notified under The Companies (Accounting Standards) Rules.139 144.278 124.39 63.057 70.4 375.107 160.nseindia.52 0.108 10.254 11.39 131.653 36.Face Value ` 1 each (Previous periods ` 5 each) Reserves excluding Revaluation Reserve (As per last Audited Balance Sheet) Earnings Per Share of ` 1 each .244) 99.com'.725.589 25.252 914 34.623 11. incorporated in Israel became a subsidiary of the Company on September 20.166 2.12.29 (` In Lakhs) Year ended 31.751.356 3. Interest & Tax Other Income Profit before Interest & Tax Net Interest Income Profit after Interest but before Tax Tax Expense Net Profit from ordinary activities after tax before minority interest Minority Interest Net Profit after minority interest Paid-up Equity Share Capital Equity Shares .2010 Audited 252. one equity share of ` 5 each of the Company is sub-divided into five equity shares of ` 1 each fully paid up. Closing [0].420 5.895 10.902 102.200 99.992 289.095 11. 6 The standalone financial results for the quarter ended December 31.390020 Corporate Office : Acme Plaza.751.68 63.145 130.452 99.000 0.956 810. Andheri (E).39 131.33 131.500 0. during the quarter.in ` (Basic & Diluted) Public Shareholding No.916 89.341 13.0 75.244 35.105.7 375.625 3. 5 The Company has only one reportable business segment namely 'Pharmaceuticals'.585 3.Taro's financial results are available on its website 'www.39 63.261 (` in Lakhs) Year ended 31.12. 4 Taro Pharmaceutical Industries Ltd(Taro).441 33. wherever considered necessary.29 102.09 Unaudited Unaudited 437. 2010.12.000 0.356 3.151.069 83.605 33.084 (1.731 184.028 101.Sun Pharmaceutical Industries Limited Regd.32 17.200 99. 2006. of Equity Shares of ` 1 each (Previous periods ` 5 each) Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group) Percentage of Equity Shares (as a % of the total share capital of the Company) b) Non-encumbered No.344 35.356 9.32 4.331 36.259 93.293 10.09 Unaudited Unaudited 76.12.704 48. 2006.006 2. Resolved [7].com) and on the websites of BSE (www. 8 Figures for the previous period / year have been regrouped / reclassified.

904 5.249 103.866 39 23 95.12.210 113 214.390020 Corporate Office : Acme Plaza.12.830 86.722 Total Sales Domestic Formulations Bulk Others Exports Formulations Bulk Others Sales Formulations Bulk Others Net Interest and Other Income Net Interest Income Other Income R&D Expenditure as % of Sales Total R&D Expenditure Capital Revenue .811 32.03.614 193.10 31.029 129.760 17.579 914 6.194 19.651 8.117 43 122 5.985 8.406 164.068 1.986 261.796 Nine Months ended 31.312 1.073 43.768 56.917 44.336 183.741 289 277 443.700 2.076 197.590 24.512 134 84 246.12.956 4.614 351.480 8.979 66.298 19.462 41.534 11.481 47. Mumbai .482 305. Tandalja.076 140.076 401.907 777 20.890 (` In Lakhs) Year ended 31.223 2.902 7.331 2.930 54.262 10.0% 9.868 11.568 14.4% 23.149 64.740 11.259 5.6% 26.2% 5.389 9.979 150.253 423 361 16.088 34.260 2.178 21.245 3.12.249 103.161 8.697 664 407.Sun Pharmaceutical Industries Limited Regd.013 10.09 Unaudited Unaudited 162.10 31. Vadodara .482 305.957 131.146 948 350 8.10 Audited 407.829 214. 2010 Quarter ended 31.09 Unaudited Unaudited 443. Andheri (E).029 53.609 36.932 8.145 6.538 1.278 168.802 3. Andheri-Kurla Road.251 4 99 162.638 89.3% 6. Office : Sun Pharma Advanced Research Centre.400059 Consolidated Unaudited Financial Results for the Quarter and Nine Months ended December 31.247 187.